Edwards Lifesciences Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Edwards Lifesciences şirketinin toplam hissedar öz sermayesi $9.6B ve toplam borcu $597.5M olup, bu da borç-öz sermaye oranını 6.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $13.0B ve $3.4B dir. Edwards Lifesciences 'in FAVÖK'ü $1.9B faiz karşılama oranı -28.5 dur. Şirketin $4.4B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
6.2%
Borç/özkaynak oranı
US$597.50m
Borç
| Faiz karşılama oranı | -28.5x |
| Nakit | US$4.45b |
| Eşitlik | US$9.61b |
| Toplam yükümlülükler | US$3.36b |
| Toplam varlıklar | US$12.97b |
Son finansal sağlık güncellemeleri
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24
Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Recent updates
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: EW 'nin kısa vadeli varlıkları ( $6.7B ) kısa vadeli yükümlülüklerini ( $1.9B ) aşıyor.
Uzun Vadeli Yükümlülükler: EW şirketinin kısa vadeli varlıkları ( $6.7B ) uzun vadeli yükümlülüklerini ( $1.4B ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: EW şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: EW 'nin borç/öz sermaye oranı son 5 yılda 15.6% seviyesinden 6.2% seviyesine düştü.
Borç Kapsamı: EW 'nin borcu işletme nakit akışı ( 135% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: EW ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.